Key facts
- This page summarizes Mark Baldry's Form 4 filing for X4 Pharmaceuticals, Inc (XFOR).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 27 Jan 2025, 18:15.
Mark Baldry - 23 Jan 2025 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- XFOR
- Reported as of
- 23 Jan 2025
- Net transaction value
- -$13,241
- SEC form
- 4
- Accepted by SEC
- 27 Jan 2025, 18:15:32 UTC
- Prior SEC filing
- 08 Oct 2024
- Next SEC filing
- 03 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Adam S. Mostafa, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mark Baldry filed Form 4 for X4 Pharmaceuticals, Inc (XFOR) on 27 Jan 2025.
Change
- Previous filing in this sequence was filed on 08 Oct 2024.
- Current net transaction value: -$13,241.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
XFOR
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +74,773
- Change %
- +154%
- Price
- $0.000000
- Shares after
- 123,282
- Date
- 23 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
XFOR
transaction
Common Stock
Sale
- Transaction value
- $13,241
- Shares
- -29,159
- Change %
- -24%
- Price
- $0.4541
- Shares after
- 94,123
- Date
- 24 Jan 2025
- Ownership
- Direct
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurred upon the acceptance by the European Medicines Agency of the Issuer's Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome.
Footnote F2
These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.4475 to $0.47, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.